Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hollis-Eden Pharmaceuticals has reported that additional data from preclinical studies demonstrate that its potent, second-generation compounds provided significant benefit in models of acute lung inflammation, septic shock and multiple sclerosis.
Subscribe to our email newsletter
In the studies, mice treated with second-generation investigational immune regulating hormone (IRH) compounds showed increased survival and dramatically reduced inflammation compared to placebo treated animals. Benefit was achieved with doses ranging from 0.1mg to 1.0mg, as compared to the 3mg to 6mg doses previously required to see benefit in these same models using first-generation compounds.
“The data suggest that these second-generation IRHs, which are more metabolically stable and more potent than the parent compounds, may provide benefit to patients with a number of different inflammatory and autoimmune diseases,” said Dr Christopher Reading, executive vice president of scientific development at Hollis-Eden Pharmaceuticals.
“We are seeing activity with many of our new compounds at significantly lower doses than with parent compounds. The activity we are seeing is on par with what anti-TNF-alpha therapy achieves in these same models,” he added.